Business Wire

Cyclic Materials Secures USD $53M Series B Funding to Accelerate Global Expansion of Rare Earth Recycling Infrastructure

25.9.2024 14:00:00 CEST | Business Wire | Press release

Share

New equity funding will be instrumental in the opening of Cyclic Materials’ first commercial facilities in the US and Europe.

Cyclic Materials, the advanced recycling company creating a circular supply chain for rare earth elements (REEs) and other critical materials, today announced it has successfully closed an oversubscribed USD $53 million Series B equity round.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925684235/en/

Cyclic Materials' agnostic technologies enable rare earth magnets recycling out of end-of-life products such as wind turbines, EVs, MRIs or e-waste. This image shows industrial waste from an MRI machine. (Photo: Business Wire)

The funding round was led by ArcTern Ventures and supported by new investors BDC Capital’s Climate Tech Fund, Hitachi Ventures, Zero Infinity Partners, Climate Investment, and Microsoft’s Climate Innovation Fund. Existing investors Fifth Wall, BMW i Ventures, Energy Impact Partners, and Planetary Technologies also participated in the round.

This funding brings the company’s total equity raised to over USD $83 million and will enable Cyclic Materials to fast-track its international growth. Cyclic Materials will deploy this capital to build rare earth recycling infrastructure in the US and Europe, and grow its team to support its world-class operations.

“We're energized to partner with the world’s top sustainability-focused infrastructure and corporate investors to scale our technology’s impact,” said Ahmad Ghahreman, CEO and Co-Founder of Cyclic Materials. “This funding underscores the confidence in our ability to create the circular economy for rare earths needed for the clean energy transition. Not only is our technology essential for supporting sustainable domestic production of rare earths, but it will also play a critical role in re-establishing North American and European leadership in the rare earths industry.”

Importantly, Cyclic Materials’ process of recycling these rare earth materials from magnets achieves significant environmental benefits in comparison to traditional mining processes, including a reduced carbon footprint and unparalleled water efficiency.

“We seek to partner with visionary founders and technology companies that share our commitment to tackling sustainability challenges with innovative solutions,” said Marc Faucher, Managing Partner at ArcTern Ventures. “Cyclic Materials' mission-driven approach to the circular economy combined with its proprietary rare earth metals recycling processes offers a scalable decarbonization solution that contributes to the abatement of greenhouse gas emissions. This alignment with our impact-driven investment strategy is why we chose them to become a part of ArcTern’s investment portfolio.”

The Series B funding follows a USD $3.6 million grant award from Natural Resources Canada that supports the continued operation of Cyclic Materials’ commercial demonstration facility (Hub100) for producing high-purity REEs from recycled magnet material and preparing for scaling to larger operations. These recent public and private investments demonstrate the surging interest in funding companies with technology proven to address climate change and sustainable development.

“The opportunity to invest in companies like Cyclic Materials at this stage of development and scaling is scarce,” said Tobias Jahn, Partner at Hitachi Ventures. “We are impressed with their high growth potential, strong leadership, proprietary extraction processes from electronic and industrial waste, and commitment to overcoming the limited availability of rare earth elements essential for various technologies in today’s electrification era.”

Established in 2021, Cyclic Materials’ proprietary technologies are capable of economically and sustainably recovering critical raw materials from end-of-life electric vehicle motors, wind turbines, MRI machines, and data center electronic waste. Over the past year, the company forged strategic partnerships with key industry leaders such as Solvay, Vattenfall, Synetiq, and VACUUMSCHMELZE to recycle magnets containing REEs and establish a circular supply chain.

About Cyclic Materials

Established in 2021, Cyclic Materials is a cleantech company creating a circular supply chain for rare earth elements (REEs) and other critical materials for supporting the clean energy transition. Through its innovative technology, the company economically, sustainably, and domestically transforms end-of-life products into valuable raw materials that are essential to the production of electric vehicles, wind turbines, and motors for the electronics we use in our daily lives. In 2023, Cyclic Materials commissioned a commercial demonstration facility of the first stage of its process, to recover rare earth magnets from end-of-life materials using the proprietary process, Mag-Cycle™. In 2024, Cyclic Materials opened a second commercial demonstration facility, for the second stage of its process, in Kingston, Ontario where Mixed Rare Earth Oxide is produced using its proprietary hydrometallurgical technology, REEPure™. With the global market for magnets containing REEs forecasted to increase dramatically by 2030, establishing new sources of these critical materials is vital to support the electrification of the global economy. Cyclic Materials is scaling its technology across North America, Europe, and Asia. To learn more, visit cyclicmaterials.earth.

About ArcTern Ventures

ArcTern Ventures is a venture capital firm committed to addressing the climate crisis and advancing sustainability. Headquartered in Toronto, with offices in Oslo and San Francisco, ArcTern invests globally in innovative technology companies focused on climate action and sustainability—what we call Earthtech. The firm was founded on the premise that accelerating the transition to a carbon-neutral economy can disrupt industries and present an unprecedented opportunity for outsized financial returns, benefiting companies, investors, and the planet. ArcTern's latest fund, Fund III, closed in January 2024 with US$337M from leading institutional investors, with a focus on Series A and B startups. Visit www.arcternventures.com

About Hitachi Ventures

Hitachi Ventures is the corporate venture capital arm of Hitachi Ltd. With $600M assets under management, we focus on investing in early-stage and growth-stage technology companies with strategic relevance to Hitachi. With a global network and extensive experience across various industries, Hitachi Ventures supports innovative startups in their journey to disrupt markets and transform industries. The firm’s investment areas span from environmental tech & circularity, energy, AI & digital technologies, to industrial automation and life sciences. For more information visit www.hitachi-ventures.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240925684235/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye